Avanir to sell Merck's Januvia in long-term care settings
This article was originally published in Scrip
Executive Summary
Avanir Pharmaceuticals has entered into an exclusive, three-year agreement with Merck & Co to co-promote Merck's type 2 diabetes therapies Januvia (sitagliptin) and the sitagliptin family of products in the long-term care institutional setting in the US.